Skip to main content
Oncotarget logoLink to Oncotarget
. 2024 Feb 8;15:123. doi: 10.18632/oncotarget.28560

Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

Changhwan Yoon 1, Kevin K Chang 1, Jun Ho Lee 1, William D Tap 2, Charles P Hart 3, M Celeste Simon 4, Sam S Yoon 1,
PMCID: PMC10852056  PMID: 38329733

This article has been retracted: Oncotarget has completed its investigation of this paper. A concerned reader informed the journal of several instances of image duplication. Namely, there is internal duplication between two images in Figure 3C. In addition, two images in Figure 3C are duplicates of images in Figure 6F from a previously published paper [1]. There is also a second internal duplication of one image in both Figures 4B and 6B. In light of these issues, the journal requested clarification regarding these images from the authors. The provided explanations were deemed unacceptable by the Scientific Integrity Office. Based on these facts, Oncotarget has decided to retract this paper.

Original article: Oncotarget. 2016; 7:42844–42858. 42844-42858. https://doi.org/10.18632/oncotarget.10212

REFERENCES

  • 1. Yoon C, Lee HJ, Park DJ, Lee YJ, Tap WD, Eisinger-Mathason TS, Hart CP, Choy E, Simon MC, Yoon SS. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br J Cancer. 2015; 113:46–56. 10.1038/bjc.2015.186. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES